Apyx Medical Publishes Two Peer-Reviewed Studies on Renuvion's Efficacy in Body Contouring Procedures

Apyx Medical announced two peer-reviewed publications evaluating the use of Renuvion in body contouring procedures. A prospective, randomized controlled trial found that patients treated with Renuvion demonstrated improvements in abdominal skin laxity and excess skin, with higher satisfaction scores at 6 months, 1 year, and 2 years post-procedure. A retrospective study of 77 patients found no significant difference in the occurrence of adverse events between Renuvion and ultrasound-assisted lipoabdominoplasty groups.

Apyx Medical Corporation (Nasdaq: APYX) has announced the publication of two peer-reviewed clinical studies evaluating the use of Renuvion in body contouring procedures. The studies, published in the journals Aesthetic Plastic Surgery and Aesthetic Surgery Journal Open Forum, offer insights into the safety and efficacy of Renuvion in addressing loose and lax skin post-liposuction.

The first study, authored by Mauro Barone, MD et al. and published in Aesthetic Plastic Surgery, is a prospective, randomized controlled trial involving 76 patients who underwent lipoabdominoplasty with or without Renuvion. The trial found that patients treated with Renuvion demonstrated significant improvements in abdominal skin laxity and excess skin, with higher satisfaction scores at 6 months, 1 year, and 2 years post-procedure. These results were measured using validated BODY-Q questionnaires and independent physician-rated VAS scale scores. The study concluded that the addition of Renuvion resulted in greater improvements compared to lipoabdominoplasty alone, without an increased rate of complications [1].

The second study, authored by Paul Vanek, MD and published in Aesthetic Surgery Journal Open Forum, is a retrospective analysis of 77 patients who underwent ultrasound-assisted lipoabdominoplasty (UAL) with or without Renuvion. The study found no statistically significant difference between groups in the occurrence of significant adverse events. Notably, the Renuvion group did not experience a higher incidence of complications, despite undergoing more concurrent procedures and longer surgical times [2].

Charlie Goodwin, President and Chief Executive Officer of Apyx Medical, commented on the publications, stating, "We estimate over 15 million patients are currently using GLP-1 drugs, many of which, we believe, will seek treatment for loose and lax skin due to the associated rapid weight loss. Renuvion is the only FDA-cleared device for addressing loose and lax skin post-liposuction in aesthetic body contouring procedures, and we are uniquely positioned to treat this growing patient population." Goodwin also highlighted the studies' role in advancing evidence-based innovation in aesthetic surgery [1].

These publications further solidify Apyx Medical's commitment to advancing evidence-based innovation in aesthetic surgery and reinforce the growing body of evidence supporting the safety and value of Renuvion in aesthetic body contouring procedures.

References:

[1] https://www.globenewswire.com/news-release/2025/04/29/3070104/0/en/Apyx-Medical-Corporation-Announces-Two-Peer-Reviewed-Publications-on-the-Use-of-Renuvion-in-Abdominal-Body-Contouring-Procedures.html
[2] https://www.globenewswire.com/news-release/2025/04/29/3070104/0/en/Apyx-Medical-Corporation-Announces-Two-Peer-Reviewed-Publications-on-the-Use-of-Renuvion-in-Abdominal-Body-Contouring-Procedures.html